Centre for Youth Mental, University of Melbourne, Melbourne, Australia.
Orygen, Melbourne, Australia.
Dialogues Clin Neurosci. 2024;26(1):64-76. doi: 10.1080/19585969.2024.2413476. Epub 2024 Oct 12.
Assessing candidate gene sequence variations and expression helps to understand methamphetamine use disorder and inform potential treatments. We investigated single nucleotide polymorphisms (SNPs) and gene expression in four candidate genes: and between controls and people with methamphetamine use disorder.
Fifty-nine participants (29 people with methamphetamine use disorder and 30 controls) completed a clinical interview, cognitive tasks, and provided a blood sample. , and SNPs were genotyped, and gene expression was assessed with real-time quantitative PCR.
Pro4Thr was associated with methamphetamine use disorder (OR = 6.22; = .007). variants, rs363227 and rs363387, were negatively associated with methamphetamine use severity ( = .003) and positively associated with inhibitory control performance ( = .006), respectively. Val66Met was associated with the severity of use ( = .008). and mRNA levels were lower in people who use methamphetamine relative to controls ( = .021 and .010, respectively).
is identified for the first time to play a potential role in methamphetamine use disorder. Lower levels of blood and mRNA in people with methamphetamine use disorder suggest reduced monoamine reuptake, recycling, or release, and higher anandamide levels in this clinical group, which may be potential therapeutic targets.
评估候选基因序列变异和表达有助于了解甲基苯丙胺使用障碍，并为潜在的治疗方法提供信息。我们研究了四个候选基因中的单核苷酸多态性（SNP）和基因表达：和 在对照组和甲基苯丙胺使用障碍患者之间。
59 名参与者（29 名甲基苯丙胺使用障碍患者和 30 名对照者）完成了临床访谈、认知任务，并提供了血液样本。、和 SNPs 进行了基因分型，实时定量 PCR 评估了基因表达。
Pro4Thr 与甲基苯丙胺使用障碍有关（OR=6.22；=0.007）。rs363227 和 rs363387 变体与甲基苯丙胺使用严重程度呈负相关（=0.003），与抑制控制表现呈正相关（=0.006），分别。Val66Met 与使用严重程度有关（=0.008）。与对照组相比，使用甲基苯丙胺的人 和 mRNA 水平较低（=0.021 和.010，分别）。
首次确定 在甲基苯丙胺使用障碍中发挥潜在作用。甲基苯丙胺使用障碍患者血液中 和 mRNA 水平较低表明单胺再摄取、再循环或释放减少，而该临床组中花生四烯酸水平升高，这可能是潜在的治疗靶点。
